Prof. DDr. Markus Jörger
ESMO 2018: An oral FGFR inhibitor for head and neck cancer
PD DDr. Markus Jörger, Department for Medical Oncology and Hematology of Kantonsspital St.Gallen on a phase I trial investigating the treatment of head and neck cancer with rogaratinib, an oral FGFR inhibitor.
Source: ESMO 2018 Congress
Joerger M et al., Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression. Abstract #1056PD
Weitere Beiträge zum Schwerpunkt: